Shares of Bristol Myers Squibb Co. BMY slid 1.43% to $57.38 Wednesday, on what proved to be an all-around mixed trading ...

This was the stock's fifth consecutive day of gains.

Bristol-Myers Squibb released financial results for Q4 2024. Check out why I am upgrading BMY stock's rating from 'Buy' to ...

We recently published a list of Dividend Stock Portfolio For Income: Top 10 Stocks to Buy. In this article, we are going to ...

A weekly summary of insider trading highlighting a few notable buying and selling by investors, directors and executives. The ...

In other words, for those looking for "forever stocks," it's not a bad idea to look in this sector. And even with a modest ...

Bristol Myers Squibb (BMY) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the ...

Bristol Myers' Opdivo plus Yervoy gets FDA Priority Review for first-line MSI-H/dMMR metastatic colorectal cancer, with a ...

The FDA accepted a supplemental biologics license application for Opdivo plus Yervoy as a first-line treatment for some adult ...

US-based pharmaceutical company Bristol Myers Squibb (BMS) has reported results from the POETYK PSO long-term extension (LTE) ...

In a Chinese trial, trastuzumab rezetecan induced a 73% response rate in previously treated HER2-mutant non-small cell lung cancer (NSCLC). The safety profile of the novel antibody-drug conjugate was ...